HebeCell and Logomix form a strategic partnership to develop gene-edited NK cells and genetic modifications to create next gen designer NK cells.
HebeCell and Logomix form a strategic partnership to develop gene-edited NK cells and genetic modifications to create next gen designer NK cells.
Our President and CEO John Lu was recently interviewed by IMAPAC on key developments, technologies and challenges in Asia's Cell and Gene Therapy Industry. You can find the full interview in the PDF attached.
Proteintech and HebeCell announce their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor (nCAR) technology for the development and commercialization of iPSC-derived natural killer (iPSC-nCAR-NK) cells, a promising cellular immunotherapy treatment for cancer and other diseases.
Ankarys Therapeutics Inc. (Ankarys), Applied StemCell, Inc. (ASC), and HebeCell Corp. (HebeCell) announced that they have entered into a strategic collaboration to co-develop allogeneic induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR) NK cell therapeutics targeting hematological malignancies.
HebeCell Corp (“HebeCell”) today announced that it has closed a US$10 million Pre-Series A financing to further advance the research and development of its leading patented scalable natural killer (NK) cell platform technology. Aceso Biotech Venture Fund invested in this round of financing.
The design of HebeCell’s 3D NK cell manufacture platform mimics lymph node environments of NK cell development in vivo. Compared to other currently available systems, our platform has 6 major technical advantages.
HebeCell will attend the Phacilitate Leaders World & World Stem Cell Summit 2020 as an associate sponsor from January 21-24, 2020 in Miami.